Trials / Completed
CompletedNCT02463643
To Evaluate Efficacy and Safety of Z-215 in Erosive Esophagitis
A Randomized, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Z-215 Compared With Rabeprazole Sodium in the Treatment of Erosive Esophagitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 503 (actual)
- Sponsor
- Zeria Pharmaceutical · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of Z-215 (10 mg, 20 mg, 40 mg) , compared with Rabeprazole Sodium 10mg in patients with erosive esophagitis of Grade A to D as defined by the LA classification grading system.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Z-215 10mg | Z-215 10mg, capsules |
| DRUG | Z-215 20mg | Z-215 20mg, capsules |
| DRUG | Z-215 Placebo | Z-215 placebo-matching capsules |
| DRUG | Rabeprazole Sodium | Rabeprazole Sodium 10mg tablets |
| DRUG | Rabeprazole Sodium Placebo | Rabeprazole Sodium Placebo placebo-matching tablets |
Timeline
- Start date
- 2015-05-01
- Primary completion
- 2016-10-01
- Completion
- 2017-03-01
- First posted
- 2015-06-04
- Last updated
- 2017-07-02
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02463643. Inclusion in this directory is not an endorsement.